Vanguard Group
CUE icon

Vanguard Group’s Cue Biopharma CUE Stock Holding History

Vanguard Group’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$919K Sell
100,468
-843
-0.8% -$15.5K ﹤0.01% 3795
2025
Q3 		$2.19M Sell
101,311
-4,934
-5% -$116K ﹤0.01% 3553
2025
Q2 		$2.17M Buy
106,245
+29,050
+38% +$620K ﹤0.01% 3510
2025
Q1 		$2.11M Buy
77,195
+8,656
+13% +$321K ﹤0.01% 3478
2024
Q4 		$2.24M Buy
68,539
+825
+1% +$31K ﹤0.01% 3533
2024
Q3 		$1.54M Hold
67,714
– – ﹤0.01% 3637
2024
Q2 		$2.52M Sell
67,714
-8,398
-11% -$415K ﹤0.01% 3486
2024
Q1 		$4.32M Buy
76,112
+5,015
+7% +$354K ﹤0.01% 3351
2023
Q4 		$5.63M Buy
71,097
+267
+0.4% +$19.1K ﹤0.01% 3238
2023
Q3 		$4.89M Buy
70,830
+2,546
+4% +$249K ﹤0.01% 3260
2023
Q2 		$7.48M Buy
68,284
+13,164
+24% +$1.55M ﹤0.01% 3113
2023
Q1 		$5.9M Buy
55,120
+4,156
+8% +$396K ﹤0.01% 3222
2022
Q4 		$4.36M Buy
50,964
+220
+0.4% +$20.1K ﹤0.01% 3370
2022
Q3 		$3.4M Hold
50,744
– – ﹤0.01% 3521
2022
Q2 		$3.79M Sell
50,744
-4,381
-8% -$512K ﹤0.01% 3519
2022
Q1 		$8.07M Buy
55,125
+3,415
+7% +$724K ﹤0.01% 3265
2021
Q4 		$17.5M Sell
51,710
-747
-1% -$289K ﹤0.01% 2917
2021
Q3 		$22.9M Buy
52,457
+533
+1% +$186K ﹤0.01% 2790
2021
Q2 		$18.1M Buy
51,924
+109
+0.2% +$42.2K ﹤0.01% 2901
2021
Q1 		$19M Buy
51,815
+3,664
+8% +$1.51M ﹤0.01% 2810
2020
Q4 		$18.1M Buy
48,151
+2,120
+5% +$847K ﹤0.01% 2689
2020
Q3 		$20.8M Buy
46,031
+1,442
+3% +$831K ﹤0.01% 2440
2020
Q2 		$32.8M Buy
44,589
+13,679
+44% +$9.91M ﹤0.01% 2202
2020
Q1 		$13.2M Buy
30,910
+1,253
+4% +$608K ﹤0.01% 2486
2019
Q4 		$14.1M Buy
29,657
+4,485
+18% +$1.41M ﹤0.01% 2691
2019
Q3 		$6.37M Buy
25,172
+4,767
+23% +$1.15M ﹤0.01% 3041
2019
Q2 		$5.5M Buy
20,405
+5,155
+34% +$1.28M ﹤0.01% 3131
2019
Q1 		$3.54M Buy
15,250
+5,441
+55% +$1.03M ﹤0.01% 3267
2018
Q4 		$1.38M Sell
9,809
-12,245
-56% -$2.22M ﹤0.01% 3471
2018
Q3 		$5.99M Sell
22,054
-224
-1% -$64.7K ﹤0.01% 3159
2018
Q2 		$7.93M Buy
22,278
+7,216
+48% +$2.87M ﹤0.01% 3016
2018
Q1 		$6.35M Buy
+15,062
New +$6.87M ﹤0.01% 3046

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $1.84B AUM 19.34% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

Vanguard Group's CUE Position: Q4 2025 in Review

Vanguard Group reduced its Cue Biopharma (CUE) stake by 0.83% in Q4 2025, selling an estimated $15.5K and leaving 100,468 shares worth $919K. The position accounts for ﹤0.01% of the portfolio, ranked #3795.

Vanguard Group first reported a position in CUE in Q1 2018 and has held it in 32 quarters since. The position peaked at $32.8M in Q2 2020. 47 funds tracked by Wall St. Rank hold CUE as of Q4 2025.

  • Vanguard Group held 100,468 shares of Cue Biopharma worth $919K as of Q4 2025.
  • Vanguard Group sold 843 Cue Biopharma shares in Q4 2025, an estimated $15.5K.
  • Cue Biopharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3795 holding.
  • Vanguard Group first reported a position in Cue Biopharma in Q1 2018 and has held it in 32 quarters since.
  • Vanguard Group's Cue Biopharma position peaked at $32.8M in Q2 2020.
  • 47 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.